Immunomodulatory cell therapy in sepsis: Have we learnt lessons from the past?

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 10, 2010, Pages 1109-1112

  Monneret, Guillaume ^a   Venet, Fabienne ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

immunotherapy; inflammation; mesenchymal stem cells; sepsis; septic shock

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 7 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE STORM; FLUID RESUSCITATION; HUMAN; IMMUNOMODULATORY CELL THERAPY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 77958160858     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.107     Document Type: Review

References (24)

1. Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce infammation while enhancing bacterial clearance and improving survival in sepsis. Am. J. Respir. Crit. Care Med. DOI: 10.1164/rccm.201001-0010OC (2010) (Epub ahead of print).
2. Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E (2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15(1), 42-49 (2009).
3. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 4(9), e269 (2007).
4. Meduri GU. Clinical review: a paradigm shift: the bidirectional effect of infammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit. Care 6(1), 24-29 (2002).
5. Zeni F, Freeman B, Natanson C. Antiinfammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25(7), 1095-1100 (1997).
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348(2), 138-150 (2003).
7. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol. Med. 14 (1-2), 64-78 (2008).
8. Dyson A, Singer M. Animal models of sepsis: why does preclinical effcacy fail to translate to the clinical setting? Crit. Care Med. 37 (1 Suppl.), S30-S37 (2009).
9. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15(5), 496-497 (2009).
10. + regulatory T cells through a TRAIL-dependent mechanism. J. Immunol. 184(12), 6766-6772 (2010).
11. Unsinger J, McGlynn M, Kasten KR et al. IL-7 promotes T cell viability, traffcking, and functionality and improves survival in sepsis. J. Immunol. 184(7), 3768-3779 (2010).
12. Benjamim CF, Lundy SK, Lukacs NW, Hogaboam CM, Kunkel SL. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 105(9), 3588-3595 (2005).
13. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol. 88(2), 233-240 (2010).
14. Muenzer JT, Davis CG, Chang K et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 78(4), 1582-1592 (2010).
15. Inoue S, Unsinger J, Davis CG et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 184(3), 1401-1409 (2010).
16. -) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35(4), 678-686 (2009).
17. Nascimento DC, Alves-Filho JE, Sonego F et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit. Care Med. 38(8), 1718-1725 (2010).
18. Cavassani KA, Carson WF 4th, Moreira AP et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 115(22), 4403-4411 (2010).
19. Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3(6), 678-681 (1997).
20. Nakos G, Malamou-Mitsi VD, Lachana A et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-γ. Crit. Care Med. 30(7), 1488-1494 (2002).
21. Meisel C, Schefold JC, Pschowski R et al. GM-CSF to reverse sepsis-associated immunosuppression: a double-blind randomized placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180(7), 640-648 (2009).
22. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp. 280, 21-27; discussion 27-36, 160-164 (2007).
23. Landelle C, Lepape A, Voirin N et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. DOI: 10.1007/s00134-010-1962-x (2010) (Epub ahead of print).
24. Hotchkiss RS, Opal S. Immunotherapy for sepsis-a new approach against an ancient foe. N. Engl. J. Med. 363(1), 87-89 (2010).